Scientists are increasingly examining retatrutide, a innovative drug from Eli Lilly, as a potential advance in weight management. Distinct from many existing approaches, retatrutide is a dual -action receptor targeting equally GLP-1 and GIP, hormones that affect appetite and glucose regulation .… Read More